Načítá se...
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
Inducible T cell costimulator (ICOS, cluster of differentiation (CD278)) is an activating costimulatory immune checkpoint expressed on activated T cells. Its ligand, ICOSL is expressed on antigen-presenting cells and somatic cells, including tumour cells in the tumour microenvironment. ICOS and ICOS...
Uloženo v:
| Vydáno v: | ESMO Open |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ https://ncbi.nlm.nih.gov/pubmed/32516116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000544 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|